Michael Sanders
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Michael Sanders has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Arthavan Selvanathan
Genetic Metabolic Disorders Service Sydney Children's Hospitals Network Sydney New South Wales Australia
1 shared publication - Bernd C. Schwahn
Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester and Division of Evolution & Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester Manchester UK
1 shared publication Beti Baraki
King’s College London
1 shared publicationElaine Murphy
Charles Dent Metabolic Unit University College London Hospital NHS Foundation Trust London UK
1 shared publication- Fiona J. White
Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
1 shared publication Helen R. Mundy
Department of Paediatric Inherited Metabolic Diseases Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust London UK
1 shared publication
Latest Publications
- 23 July 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (4)
Hepatic Glycogen Storage Disease Type IX : Long‐Term Outcomes in the UK From 89 Patients
Hepatic glycogen storage disease type IX (GSD IX) is due to a deficiency of phosphorylase kinase and is one of the most common types of GSD. We conducted a retrospective, observational cohort study on individuals with GSD IX from across the United Kingdom. We describe the natural history and long‐term outcomes for 89 individuals with GSD IX with a median age of 16.4 years (range 4 months to 73 years). This included 60 patients with IXα2, 12 with IXβ and 13 with IXγ2. We report 49 novel alleles in PHKA2, PHKB and PHKG2 . The median age at initial presentation was 2.5 years, with 82% ( n = 68) presenting with hepatomegaly and 46% ( n = 38) presenting with ketotic hypoglycaemia. Steatosis was reported in 71% ( n = 12) who had a liver biopsy. The mean Z‐score for height at initial presentation was −1.21, and this significantly improved over childhood. A spectrum of severity was seen in all subtypes, with some requiring more intensive dietary management after initial presentation and others requiring no formal dietary treatment at all. No patients developed adenomas or hepatocellular carcinomas, and 75% ( n = 33) of adults were on no dietary therapy. Individuals with IXγ2 had a more severe disease course and had significantly worse biochemistry at initial presentation compared to other subtypes. They were diagnosed at a younger age and required more intensive dietary management across the lifespan. We believe that GSD IXγ2 is an ideal target for novel therapies. We recommend regular monitoring and multidisciplinary input in all patients with GSD IX and encourage more formal assessment of protein intake with each review.
- 23 July 2026
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (4)
Hepatic Glycogen Storage Disease Type IX : Long‐Term Outcomes in the UK From 89 Patients
Hepatic glycogen storage disease type IX (GSD IX) is due to a deficiency of phosphorylase kinase and is one of the most common types of GSD. We conducted a retrospective, observational cohort study on individuals with GSD IX from across the United Kingdom. We describe the natural history and long‐term outcomes for 89 individuals with GSD IX with a median age of 16.4 years (range 4 months to 73 years). This included 60 patients with IXα2, 12 with IXβ and 13 with IXγ2. We report 49 novel alleles in PHKA2, PHKB and PHKG2 . The median age at initial presentation was 2.5 years, with 82% ( n = 68) presenting with hepatomegaly and 46% ( n = 38) presenting with ketotic hypoglycaemia. Steatosis was reported in 71% ( n = 12) who had a liver biopsy. The mean Z‐score for height at initial presentation was −1.21, and this significantly improved over childhood. A spectrum of severity was seen in all subtypes, with some requiring more intensive dietary management after initial presentation and others requiring no formal dietary treatment at all. No patients developed adenomas or hepatocellular carcinomas, and 75% ( n = 33) of adults were on no dietary therapy. Individuals with IXγ2 had a more severe disease course and had significantly worse biochemistry at initial presentation compared to other subtypes. They were diagnosed at a younger age and required more intensive dietary management across the lifespan. We believe that GSD IXγ2 is an ideal target for novel therapies. We recommend regular monitoring and multidisciplinary input in all patients with GSD IX and encourage more formal assessment of protein intake with each review.
- Open Access
- 28 October 2025
- Published by Taylor & Francis in Perspectives: Policy and Practice in Higher Education
- Vol. 30 (1) , 76-85
Using RCTs to evaluate the impacts of targeting interventions with analytics: approaches and challenges
- 28 October 2025
- Published by Taylor & Francis in Perspectives: Policy and Practice in Higher Education
- Vol. 30 (1) , 76-85
Open AccessUsing RCTs to evaluate the impacts of targeting interventions with analytics: approaches and challenges